BackPfizer Overview
Pfizer Inc.

Pfizer Target Price

Where could PFE trade next? Consensus target price: $28.

Get informed when a big investor buys or sells

+ Follow

Share Price

$28.46

Average Target Price

$28.001.6% downside

4 analysts in the last 4 months

High: $31 | Low: $26

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Guggenheim$318.9% upsideOpen
2026-07-06HSBC$281.6% downsideOpen
2026-05-27UBSMichael Yee$275.1% downsideOpen
2026-05-14Wolfe ResearchAlexandria Hammond$268.6% downsideOpen
2026-03-17Morgan StanleyTerence Flynn$275.1% downsideOpen
2026-03-09BMO CapitalEvan David Seigerman$305.4% upsideOpen
2026-02-24RBC CapitalTrung Huynh$2512.2% downsideOpen
2026-02-19BarclaysEmily Field$2512.2% downsideOpen
2026-02-12DaiwaNarumi Nakagiri$275.1% downsideOpen
2026-01-27Cantor Fitzgerald$275.1% downsideOpen
2026-01-06UBS$2512.2% downsideOpen
2025-12-17Wolfe ResearchAlexandria Hammond$2415.7% downsideOpen
2025-12-12Morgan Stanley$281.6% downsideOpen
2025-12-10HSBCRajesh Kumar$291.9% upsideOpen
2025-11-24Guggenheim$3523% upsideOpen
2025-11-05Goldman SachsAsad Haider$268.6% downsideOpen
2025-10-31BernsteinCourtney Breen$305.4% upsideOpen
2025-10-10Morgan Stanley$3212.4% upsideOpen
2025-10-01UBSTim Anderson$281.6% downsideOpen
2025-04-22Cantor FitzgeraldCarter Gould$2415.7% downsideOpen
2024-12-18Truist FinancialRobyn Karnauskas$3212.4% upsideOpen
2024-10-30Goldman SachsChris Shibutani$3316% upsideOpen
2024-10-17BernsteinCourtney Breen$3212.4% upsideOpen
2024-09-25BarclaysCarter Gould$3212.4% upsideOpen
2024-08-07DaiwaNarumi Nakagiri$3419.5% upsideOpen
2024-07-31Wells FargoMohit Bansal$305.4% upsideOpen
2024-07-31Goldman SachsChris Shibutani$3419.5% upsideOpen
2024-07-30GuggenheimVamil Divan$3626.5% upsideOpen
2024-07-10BarclaysCarter Gould$305.4% upsideOpen
2024-05-22BMO CapitalEvan Seigerman$3626.5% upsideOpen
2024-02-14Cantor FitzgeraldLouise Chen$4558.1% upsideOpen
2023-12-14Morgan StanleyThomas Yeh$2029.7% downsideOpen
2023-11-27Morgan StanleyTerence Flynn$3730% upsideOpen
2023-02-01Morgan Stanley$4558.1% upsideOpen
2023-02-01Credit Suisse$5075.7% upsideOpen
2023-02-01Barclays$4454.6% upsideOpen
2023-02-01Atlantic Equities$4661.6% upsideOpen
2023-02-01Leerink Partners$4868.7% upsideOpen
2022-12-14Morgan Stanley$5386.2% upsideOpen
2022-12-13Goldman SachsChris Shibutani$60110.8% upsideOpen
2022-11-18Credit Suisse$5593.3% upsideOpen
2022-05-23Leerink PartnersDavid Risinger$5593.3% upsideOpen
2022-05-10Wells FargoMohit Bansal$54.4291.2% upsideOpen
2022-05-09Wells FargoMohit Bansal$5593.3% upsideOpen
2022-05-04Morgan Stanley$5282.7% upsideOpen
2022-05-02Mizuho SecuritiesVamil Divan$5593.3% upsideOpen
2022-04-15Cantor FitzgeraldLouise Chen$75163.5% upsideOpen
2022-04-10Morgan StanleyTerrance Flynn$5593.3% upsideOpen
2022-04-09CitigroupAndrew Baum$57100.3% upsideOpen
2022-03-12Bank of America SecuritiesGeoff Meacham$70146% upsideOpen

Pfizer (PFE) FAQ

Pfizer's target price stands at $28. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $28 for PFE implies 1.6% downside versus today's price ($28.46). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Pfizer's target price evolved across reporting periods, while the comparison chart places PFE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Pfizer's reading of $28 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.